Market News & Trends
physIQ & CellCarta Collaborate to Accelerate a More Precise, Personalized Approach to Vaccine Development
physIQ and CellCarta recently announced a strategic collaboration to undertake a groundbreaking study with the potential to revolutionize vaccine development…..
PAVmed Announces Successful First-in-Human Implantations of its Intraosseous Infusion System
PAVmed Inc. recently announced physicians at the Clinica Porto Azul in Barranquilla, Colombia, successfully implanted the company’s PortIO Intraosseous Infusion System in three….
PathAI Partners With Datavant to Enable Biopharma Companies to Connect Digital Pathology Data for Research
PathAI and Datavant recently announced a collaboration to enable compliant connectivity of PathAI’s pathology platform to life sciences trial data and other real-world data…..
Soligenix COVID-19 Vaccine Boosts Neutralizing Activity Against SARS-CoV-2, Including Delta & Omicron
Soligenix, Inc.recently announced the results of a booster vaccination study using CiVax (heat stable COVID-19 subunit vaccine program) in non-human primates (NHPs) demonstrating rapid enhancement…
Revel Pharmaceuticals Announces $8.4-Million Seed to Develop Repairing-Based Approaches to Reversing Aging
Revel Pharmaceuticals recently announced it has raised $8.4 million in seed financing. The oversubscribed round was led by Kizoo Technology Capital, a leading early stage…
Catalent Biologics Completes $30-Million Project for Biopharmaceutical Development & Drug Product Manufacturing in Limoges, France
Catalent recently announced the completion of a $30-million project at its facility in Limoges, France, to transform the site into a European center of excellence…
Innoforce & Hibiscus BioVentures Announce Strategic Partnership to Enable Development of Advanced Therapies
Innoforce and Hibiscus BioVentures recently announced they have formed a strategic partnership to leverage the combined resources of both organizations to advance new Advanced Therapy Medicinal Products (ATMPs) and biologic medicines in order to….
Viatris Announces Receipt of First FDA Approval for Generic Version of Symbicort Inhalation Aerosol in Partnership With Kindeva
Viatris Inc. and Kindeva Drug Delivery L.P. recently announced Mylan Pharmaceuticals Inc., a Viatris subsidiary, has received approval from the US FDA for its Abbreviated New Drug…
KemPharm Earns $1.975 Million From Corium Following FDA Approval of Donepezil Transdermal System
KemPharm, Inc. recently announced it has earned a $1.975 million fee from Corium, Inc. following the approval of Corium’s product ADLARITY (donepezil transdermal system) by…
Qualigen Therapeutics Extends Research Agreement on RAS Program
Qualigen Therapeutics, Inc. recently announced the mutual extension of a research agreement with University of Louisville Research Foundation (ULRF). The revised agreement expands the company’s…
Biogen & Eisai Amend Collaboration Agreements on Alzheimer's Disease Treatments
Biogen Inc. and Eisai Co., Ltd. recently announced the companies have amended their existing collaboration agreement on aducanumab, which is commercialized in the US as ADUHELM (aducanumab-avwa)…..
BioMed X Institute & Merck KGaA Start Second Research Project in Immunology
BioMed X recently announced the start of its new research project Regulatory T Cell Dysfunction in Autoimmunity and Inflammaging (TDA) in collaboration with Merck KGaA, Darmstadt,…
Eyenovia Announces Positive Study Results Demonstrating its Optejet Delivery Technology Reduces Conjunctival Cell Toxicity From Preserved Ophthalmic Solutions to a Level Comparable With Non-Preserved Solutions
Eyenovia, Inc. recently announced positive results from a research study conducted in collaboration with Dr. Pedram Hamrah, Interim Chairman of Ophthalmology at Tufts Medical Center, which evaluated the ocular surface….
BioIntelliSense Launches New BioButton Rechargeable Wearable Device for Continuous Medical-Grade Monitoring of 20+ Vital Signs & Biometrics
BioIntelliSense recently expanded its commitment to creating a new standard of remote patient care with the commercial launch of its medical-grade BioButton Rechargeable wearable device.…
OncoArendi Therapeutics Announces License Option Agreement With University of Michigan
OncoArendi Therapeutics S.A. recently announced it has entered into an option-to-license agreement with Innovation Partnerships at the University of Michigan (U-M) to develop novel small…
NeuBase Therapeutics Presents New Preclinical Data for its Myotonic Dystrophy Type 1 Program Demonstrating Splice Rescue, Nuclear Aggregate Resolution & Myotonia Reversal
NeuBase Therapeutics, Inc. recently announced new preclinical data for its lead development candidate, NT-0231.F, to treat myotonic dystrophy type 1 (DM1). ….
Phathom Pharmaceuticals Submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis
Phathom Pharmaceuticals, Inc. recently announced it has submitted a new drug application (NDA) to the US FDA for the use of vonoprazan as a treatment…
Oxford Biomedica Broadens its Viral Vector Capabilities With the Launch of Oxford Biomedica Solutions
Oxford Biomedica plc recently announced it has completed its deal with Homology Medicines Inc. to establish Oxford Biomedica Solutions LLC, a new US-based full scope,…
Synthetic Biologics Completes Acquisition of VCN Biosciences
Synthetic Biologics, Inc. recently announced it has completed the acquisition of VCN Biosciences, S.L. (VCN) following the satisfaction of all closing conditions…..
Vetter’s Extraordinary Performance Sweeps the Board at the 2022 CMO Leadership Awards
Vetter recently announced it has won the 2022 CMO Leadership Awards in all six core categories – quality, expertise, compatibility, capabilities, reliability and service…..
